Walleye Trading’s AbCellera Biologics ABCL Stock Holding History

Walleye Trading’s Portfolio ABCL Stock Details ABCL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$350K	Buy	44,609 +36,931	+481%	+$181K	﹤0.01%	2867
2026 Q1	$26.8K	Sell	7,678 -2,168	-22%	-$7.8K	﹤0.01%	3810
2025 Q4	$33.7K	Buy	+9,846	New	+$44K	﹤0.01%	4035
2024 Q1	–	Sell	-748	Closed	-$4.27K	–	4672
2023 Q4	$4.27K	Buy	748 +210	+39%	+$973	﹤0.01%	4737
2023 Q3	$2.48K	Sell	538 -6,995	-93%	-$42.6K	﹤0.01%	4746
2023 Q2	$48.7K	Sell	7,533 -4,096	-35%	-$28K	﹤0.01%	3969
2023 Q1	$87.7K	Buy	+11,629	New	+$106K	﹤0.01%	3903
2022 Q4	–	Sell	-36,525	Closed	-$361K	–	4905
2022 Q3	$361K	Buy	+36,525	New	+$401K	﹤0.01%	3217

Other funds holding ABCL

TWC

TD Waterhouse Canada Toronto, Ontario, Canada $38B AUM 39.14% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

National Bank of Canada Montreal, Quebec, Canada $140B AUM 46.34% 1-Year Est. Return

CMF

Counterpoint Mutual Funds San Diego, California $1.01B AUM 37.65% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Guardian Partners Toronto, Canada $1.11B AUM 38.73% 1-Year Est. Return

SOMRS

State of Michigan Retirement System Lansing, Michigan $22.6B AUM 40.24% 1-Year Est. Return

DRP

Decker Retirement Planning Levi, Utah $294M AUM 97.44% 1-Year Est. Return

Daiwa Securities Group Tokyo, Japan $51.1B AUM 35.55% 1-Year Est. Return

CFG

Citizens Financial Group Providence, Rhode Island $8.3B AUM 27.66% 1-Year Est. Return

Walleye Trading's ABCL Position: Q2 2026 in Review

Walleye Trading increased its AbCellera Biologics (ABCL) stake by 481% in Q2 2026, buying an estimated $181K and bringing the position to 44,609 shares worth $350K. The position accounts for ﹤0.01% of the portfolio, ranked #2867.

Walleye Trading first reported a position in ABCL in Q3 2022 and has held it in 8 quarters since. The position peaked at $361K in Q3 2022. 66 funds tracked by Wall St. Rank hold ABCL as of Q2 2026.

Walleye Trading held 44,609 shares of AbCellera Biologics worth $350K as of Q2 2026.
Walleye Trading bought 36,931 AbCellera Biologics shares in Q2 2026, an estimated $181K.
AbCellera Biologics made up ﹤0.01% of Walleye Trading's portfolio in Q2 2026, its #2867 holding.
Walleye Trading first reported a position in AbCellera Biologics in Q3 2022 and has held it in 8 quarters since.
Walleye Trading's AbCellera Biologics position peaked at $361K in Q3 2022.
66 funds tracked by Wall St. Rank held AbCellera Biologics as of Q2 2026.

Based on Walleye Trading's 13F filing for Q2 2026, filed 3 Aug 2026.